John Schieszer, MA

Contributing Writer https://www.cancertherapyadvisor.com

John Schieszer is an award winning medical journalist who produces The Medical Minute podcasts. John received his BA in journalism from the University of Missouri-Columbia School of Journalism and his MA in english from the University of Missouri-St. Louis. In 1990, John was awarded the Case Western Reserve University School of Medicine’s Third Annual Fellowship for Journalists in Biomedical Research. In 1992, he completed a Medical Fellowship at the Marine Biological Laboratories in Woods Hole, Massachusetts.

All articles by John Schieszer, MA

Safety and Efficacy Sorafenib Treatment for Hepatocellular Carcinoma Among Age Groups

Gastrointestinal Cancers

Upfront RT Plus Nivolumab May Benefit Patients With Unresectable Hepatocellular Carcinoma

John Schieszer, MA

September 24, 2019

The objective response rate as determined by mRECIST criteria was 35%, which was substantially higher than historical controls.

Prostate Cancer

Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 Mutations

John Schieszer, MA

September 24, 2019

Men with the BRCA1 and BRCA2 mutation have absolute lifetime risks for developing prostate cancer of 29% and 60%, respectively, according to investigators.

The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.

Hematologic Cancers

Treatment Delays With CAR-T Therapy: A High Price to Pay

John Schieszer, MA

September 11, 2019

A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.

Squamous cell carcinoma of the esophagus

Head and Neck Cancer

Comparison Study Shows Predictive Value for CSCC of the Head and Neck of BWH vs AJCC 8

John Schieszer, MA

September 3, 2019

A team of researchers sought to determine if BWH Tumor Classification System classified tumors more accurately than AJCC 8, and their sensitivity and specificity for predicting poor outcomes.

Fracture risk after urolithiasis highest among males aged 10 to 19 years and females aged 30 to 39.

Prostate Cancer

Skeletal-Related Events Common After CRPC Development

John Schieszer, MA

August 13, 2019

Large observational study reveals a 40% cumulative incidence rate of first skeletal-related events following development of castration-resistant prostate cancer.

Renal Cell Carcinoma

Study Comparing Targeted With Nontargeted Therapies in Patients With Metastatic RCC May Not Account for Recent Advances in Immunotherapy

John Schieszer, MA

July 16, 2019

There has been a sea change in outcomes from patients treated before 2007 for renal cell carcinoma, according to an expert.

Patients who received elotuzumab plus pomalidomide and dexamethasone demonstrated longer survival.

Multiple Myeloma

Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma

John Schieszer, MA

June 25, 2019

Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.

Prostate Cancer

Neoadjuvant Combo Reduces Volume of High-Risk Prostate Tumors

John Schieszer, MA

June 21, 2019

Abiraterone plus prednisone combined with leuprolide decreases tumor size compared with leuprolide alone in men with high-risk prostate cancer.

Prostate Cancer

Prostate Cancer ADT Found to Increase Depression Risk

John Schieszer, MA

April 24, 2019

Men who receive androgen deprivation therapy after radical prostatectomy have a nearly 2-fold increased risk of depression compared with those who receive no post-surgical treatment.

Hematologic Cancers

Optimal Approaches to Treating Venous Thromboembolism in Patients With Cancer

John Schieszer, MA

April 8, 2019

Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.

Next post in Hematologic Cancers